IL304491A - Methods to reduce cardiovascular risks - Google Patents

Methods to reduce cardiovascular risks

Info

Publication number
IL304491A
IL304491A IL304491A IL30449123A IL304491A IL 304491 A IL304491 A IL 304491A IL 304491 A IL304491 A IL 304491A IL 30449123 A IL30449123 A IL 30449123A IL 304491 A IL304491 A IL 304491A
Authority
IL
Israel
Prior art keywords
methods
cardiovascular risk
reducing cardiovascular
reducing
risk
Prior art date
Application number
IL304491A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of IL304491A publication Critical patent/IL304491A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL304491A 2014-03-17 2023-07-16 Methods to reduce cardiovascular risks IL304491A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US201462043182P 2014-08-28 2014-08-28
EP15305293 2015-02-26
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Publications (1)

Publication Number Publication Date
IL304491A true IL304491A (en) 2023-09-01

Family

ID=52648962

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304491A IL304491A (en) 2014-03-17 2023-07-16 Methods to reduce cardiovascular risks

Country Status (14)

Country Link
US (2) US20150284473A1 (cg-RX-API-DMAC7.html)
EP (2) EP3119810B1 (cg-RX-API-DMAC7.html)
JP (3) JP2017509624A (cg-RX-API-DMAC7.html)
KR (3) KR20220157516A (cg-RX-API-DMAC7.html)
CN (3) CN106794244A (cg-RX-API-DMAC7.html)
AU (3) AU2015231713B2 (cg-RX-API-DMAC7.html)
CA (1) CA2942549A1 (cg-RX-API-DMAC7.html)
EA (1) EA039310B1 (cg-RX-API-DMAC7.html)
ES (1) ES2978990T3 (cg-RX-API-DMAC7.html)
HU (1) HUE066839T2 (cg-RX-API-DMAC7.html)
IL (1) IL304491A (cg-RX-API-DMAC7.html)
MX (1) MX380767B (cg-RX-API-DMAC7.html)
PL (1) PL3119810T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015142668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA3129996C (en) 2009-06-15 2025-09-02 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
EP3753575A1 (en) * 2014-07-16 2020-12-23 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9
KR20240017117A (ko) 2014-07-16 2024-02-06 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016046684A1 (en) 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
TW202521589A (zh) * 2018-03-06 2025-06-01 法商賽諾菲生物技術公司 降低心血管風險的方法
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
TN2021000028A1 (en) * 2018-08-17 2022-10-03 Amarin Pharmaceuticals Ie Ltd Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
DK4056176T3 (da) 2018-09-24 2024-05-06 Amarin Pharmaceuticals Ie Ltd Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CA3192235A1 (en) * 2019-11-07 2021-05-14 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
WO2021097120A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20230312750A1 (en) * 2019-11-18 2023-10-05 Ad Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody and use thereof
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR084938A1 (es) * 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Also Published As

Publication number Publication date
KR20250006995A (ko) 2025-01-13
AU2021201118A1 (en) 2021-03-11
ES2978990T3 (es) 2024-09-23
AU2015231713B2 (en) 2020-11-19
JP2024147744A (ja) 2024-10-16
JP2017509624A (ja) 2017-04-06
KR20160132459A (ko) 2016-11-18
KR20220157516A (ko) 2022-11-29
EP4403213A2 (en) 2024-07-24
US20220144969A1 (en) 2022-05-12
EP3119810B1 (en) 2024-02-28
EP3119810A1 (en) 2017-01-25
EA201691847A1 (ru) 2017-01-30
EP4403213A3 (en) 2024-10-23
JP2022141868A (ja) 2022-09-29
CA2942549A1 (en) 2015-09-24
PL3119810T3 (pl) 2024-07-15
AU2024205254A1 (en) 2024-10-03
CN106794244A (zh) 2017-05-31
EP3119810C0 (en) 2024-02-28
EA039310B1 (ru) 2022-01-12
US20150284473A1 (en) 2015-10-08
CN114558129A (zh) 2022-05-31
HUE066839T2 (hu) 2024-09-28
WO2015142668A1 (en) 2015-09-24
CN114642661A (zh) 2022-06-21
AU2015231713A1 (en) 2016-10-20
MX380767B (es) 2025-03-12
MX2016011975A (es) 2016-12-05

Similar Documents

Publication Publication Date Title
IL304491A (en) Methods to reduce cardiovascular risks
GB201406151D0 (en) Method
GB201409558D0 (en) Method
GB201408119D0 (en) Method
GB201406155D0 (en) Method
GB201414496D0 (en) Method
GB201413240D0 (en) Method
GB201403470D0 (en) Method
GB201410022D0 (en) Method
GB201410101D0 (en) Method
GB201412802D0 (en) Method
GB201411500D0 (en) Method
GB201416849D0 (en) Method
GB201416675D0 (en) Method
GB201409234D0 (en) Method
GB201409128D0 (en) Method
GB201414181D0 (en) Method
GB201412736D0 (en) Method
GB201412226D0 (en) Method
GB201409101D0 (en) Method
IL247837A0 (en) Methods to reduce cardiovascular risks
GB201413929D0 (en) Method
GB201413612D0 (en) Method
GB201408649D0 (en) Method
GB201407971D0 (en) Method